Mechanisms limiting distribution of the threonine-protein kinase B-RaF V600E inhibitor dabrafenib to the brain: Implications for the treatment of melanoma brain metastases

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 3, 2013, Pages 655-664

  Mittapalli, Rajendar K ^a   Vaidhyanathan, Shruthi ^a   Dudek, Arkadiusz Z ^b   Elmquist, William F ^a,b  

^a Department of Pharmaceutics   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DABRAFENIB; MULTIDRUG RESISTANCE PROTEIN; VEMURAFENIB;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; EXPOSURE; FEMALE; FRIEND LEUKEMIA VIRUS; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MDCK CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ANIMALS; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL LINE; DOGS; IMIDAZOLES; INDOLES; MADIN DARBY CANINE KIDNEY CELLS; MELANOMA; MICE; MICE, KNOCKOUT; OXIMES; P-GLYCOPROTEIN; PILOT PROJECTS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; VALINE;

EID: 84874442053     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.201475     Document Type: Article

References (40)

1. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, and Elmquist WF (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 334: 147-155.
2. Agarwal S, Sane R, Ohlfest JR, and Elmquist WF (2011) The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 336:223-233.
3. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, and Hawkins M, et al. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116.
4. Bailer AJ (1988) Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16:303-309.
5. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, and Habets G, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599.
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, and Maio M, et al.; BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516.
7. Comis RL (1976) DTIC (NSC-45388) in malignant melanoma: A perspective. Cancer Treat Rep 60:165-176.
8. Dai H, Marbach P, Lemaire M, Hayes M, and Elmquist WF (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304:1085-1092.
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, and Bottomley W, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954.
10. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, and Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117:1687-1696.
11. de Vries NA, Zhao J, Kroon E, Buckle T, Beijnen JH, and van Tellingen O (2007) Pglycoprotein and breast cancer resistance protein: Two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 13:6440-6449.
12. Deeken JF and Löscher W (2007) The blood-brain barrier and cancer: Transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663-1674.
13. Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, and Schinkel AH (2012) Oral availability and brain penetration of the B-RAF(V600E) inhibitor vemurafenib can be enhanced by the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm 9:3236-3245.
14. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, and Pavlick AC, et al. (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 doseescalation trial. Lancet 379:1893-1901.
15. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC, and Besser M, et al. (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293-1300.
16. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, and Ibrahim N, et al. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-1703.
17. Garbe C, Eigentler TK, Keilholz U, Hauschild A, and Kirkwood JM (2011) Systematic review of medical treatment in melanoma: Current status and future prospects. Oncologist 16:5-24.
18. Gibney GT and Sondak VK (2012) Extending the reach of BRAF-targeted cancer therapy. Lancet 379:1858-1859.
19. Giri N, Agarwal S, Shaik N, Pan G, Chen Y, and Elmquist WF (2009) Substratedependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: Consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos 37:560-570.
20. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Jr, and Kaempgen E, et al. (2012) Dabrafenib in BRAFmutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365.
21. Hawkins BT and Davis TP (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57:173-185.
22. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, and Barretina J, et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-972.
23. Kalvass JC, Maurer TS, and Pollack GM (2007) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: Comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35:660-666.
24. Lagas JS, van Waterschoot RA, van Tilburg VA, Hillebrand MJ, Lankheet N, Rosing H, Beijnen JH, and Schinkel AH (2009) Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res 15:2344-2351.
25. Laquerre S, Arnone M, Moss K, Yang J, Fisher K, Kane-Carson LS, Smitheman K, Ward J, Heidrich B, and Rheault T, et al. (2009) A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding BRafV600E mutation. Mol Cancer Ther 8(12, Suppl)B88.
26. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, and Gaasch JA, et al. (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16:5664-5678.
27. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, and Algazi A, et al. (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087-1095.
28. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, and Logan TF, et al. (2012) Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 13: 459-465.
29. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT, and Steelman LS (2008) Targeting the Raf/MEK/ERK pathway with smallmolecule inhibitors. Curr Opin Investig Drugs 9:614-630.
30. Mittapalli RK, Vaidhyanathan S, Sane R, and Elmquist WF (2012) Impact of Pglycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: Vemurafenib (PLX4032). J Pharmacol Exp Ther 342:33-40.
31. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, and Sazegar H, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977.
32. Nedelman JR, Gibiansky E, and Lau DT (1995) Applying Bailer's method for AUC confidence intervals to sparse sampling. Pharm Res 12:124-128.
33. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, and Demby VE (2009) An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-3-chloro-4-[(3-fluorobenzyl)oxy]phenyl-6-[5-([2-(methylsulfonyl)ethyl] aminomethyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 37:439-442.
34. Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, and Markovic SN (2012) Melanoma brain metastases and vemurafenib: Need for further investigation. Mayo Clin Proc 87:976-981.
35. Schinkel AH and Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 55:3-29.
36. Siegel R, Ward E, Brawley O, and Jemal A (2011) Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236.
37. Skibber JM, Soong SJ, Austin L, Balch CM, and Sawaya RE (1996) Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 3:118-123.
38. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, and Flaherty KT, et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714.
39. Tsao H, Atkins MB, and Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998-1012.
40. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, and Kee D, et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-695.